We thank Dedeepya et al. for their thoughtful commentary on our case series describing sevelamer-associated gastrointestinal mucosal injury. Their observations provide valuable perspective on the challenges of risk stratification and clinical decision-making in this emerging area of concern. We appreciate the opportunity to address their important points.